Journals / Düzce Üniversitesi Bilim ve Teknoloji Dergisi / 2023 / Cilt: 11 - Sayı: 1

Repurposing of Triazole Drugs to Combat Common Cancer Cases

Triazol İlaçlarının Yaygın Kanser Vakalarıyla Mücadelede Yeniden Kullanımı

Pages
276–287
Publication Date
2023-01-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results revealed that both of the drugs had a low inhibitory effect on A549 cell proliferation, whereas they caused promising inhibition on MCF-7 and MDA-MB-231 cell proliferation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cancer with its prevalence and high mortality rates is an important problem that health authorities are trying to deal with all over the world.
📊
Key Findings & Data:According to the data of the International Agency for Research on Cancer, 19.3 million new cancer cases occurred worldwide in 2020, and unfortunately, about 10 million of them resulted in death.
💡
Conclusion & Impact:Results revealed that both of the drugs had a low inhibitory effect on A549 cell proliferation, whereas they caused promising inhibition on MCF-7 and MDA-MB-231 cell proliferation.
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:meme kanseri · flukonazol · itrakonazol

Abstract

Cancer with its prevalence and high mortality rates is an important problem that health authorities are trying to deal with all over the world. According to the data of the International Agency for Research on Cancer, 19.3 million new cancer cases occurred worldwide in 2020, and unfortunately, about 10 million of them resulted in death. The discovery of new drugs is compulsory due to restrictions such as the side effects of currently used anti-cancer drugs, drug resistance developing over time, and so on. Unfortunately the development of novel drugs requires especially a long time and a huge amount of cost. At this point, the repurposing approach, which refers to the secondary use of various drugs that was approved by FDA for other purposes, has a vital importance. In this study, the anti-proliferative effects of ICZ and FCZ, which are actually antifungal drugs, on breast (MCF-7 and MDA-MB-231) and lung (A549) cancer cells were evaluated. Results revealed that both of the drugs had a low inhibitory effect on A549 cell proliferation, whereas they caused promising inhibition on MCF-7 and MDA-MB-231 cell proliferation.

Özet

Yaygınlığı ve yüksek ölüm oranları ile kanser, tüm dünyada sağlık otoritelerinin başa çıkmaya çalıştığı önemli bir sorundur. Uluslararası Kanser Araştırmaları Ajansı'nın verilerine göre 2020 yılında dünya genelinde 19.3 milyon yeni kanser vakası meydana gelmiş ve ne yazık ki, bunların yaklaşık 10 milyonu ölümle sonuçlanmıştır. Halihazırda kullanılan anti-kanser ilaçlarının yan etkileri, zamanla gelişen ilaç direnci vb. kısıtlamalar nedeniyle yeni ilaçların keşfi zorunludur. Ne yazık ki, yeni ilaçların geliştirilmesi özellikle uzun bir zaman ve büyük bir maliyet gerektirmektedir. Bu noktada FDA tarafından farklı amaçlarla onaylanan çeşitli ilaçların başka amaçlarla sekonder kullanımını ifade eden yeniden kullanım yaklaşımı hayati bir önem taşımaktadır. Bu çalışmada aslında antifungal ilaçlar olan ICZ ve FCZ'nin meme (MCF-7 ve MDA-MB-231) ve akciğer (A549) kanser hücreleri üzerindeki antiproliferatif etkileri değerlendirilmiştir. Sonuçlar, her iki ilacın da A549 hücre proliferasyonu üzerinde düşük bir inhibitör etkiye sahip olduğunu, buna karşın MCF-7 ve MDA-MB-231 hücre proliferasyonu üzerinde umut verici bir inhibisyona neden olduklarını ortaya koymuştur.

🔖

Cite This Article

CENGİZ, S., YARDIMCI, B. K. (2023). Repurposing of Triazole Drugs to Combat Common Cancer Cases. Düzce Üniversitesi Bilim ve Teknoloji Dergisi, Cilt: 11 - Sayı: 1, 276–287. https://ajindex.com/articles/879582

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. O. Prakash, A. Kumar, P. Kumar and Ajeet, “Anticancer potential of plants and natural products: A review,” American Journal of Pharmacological Sciences, vol. 1(6), pp. 104-115, Dec. 2013, doi:10.12691/ajps-1-6-1
  2. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman and F. Bray, “Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012,” Int J Cancer, vol. 136(5), pp. E359-E386, Mar. 2015, doi:10.1002/ijc.29210
  3. J.F. Alhmoud, J.F. Woolley, A.E. Al Moustafa and M.I. Malki, “DNA Damage/Repair Management in Cancers,” Cancers, vol. 12(4), Apr. 2020, Art no. 1050, doi:10.3390/cancers12041050
  4. R.G. Amaral, S.V.F. Gomes, A.R. Antoniolli, M.C. dos Santos Luciano, C. do Ó Pessoa, L.N. Andrade, P. Severino, G.C. Brandão, L.M. Bomfim, D.P. Bezerra, J.M. David and A.A. Carvalho, “Evaluation of the cytotoxic potential of extracts from the genus Passiflora cultived in Brazil against cancer cells,” bioRxiv, Jun. 2018, doi:10.1101/337253
  5. M. Hedvat, L. Emdad, S.K. Das, K. Kim, S. Dasgupta, S. Thomas, B. Hu, S. Zhu, R. Dash, B.A. Quinn, R.A. Oyesanya, T.P. Kegelman, U.K. Sokhi, S. Sarkar, E. Erdogan, M.E. Menezes, P. Bhoopathi, X.-Y. Wang, M.G. Pomper, J. Wei, B. Wu, J.L. Stebbins, P.W. Diaz, J.C. Reed, M. Pellecchia, D. Sarkar and P.B. Fisher, “Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules,” Anticancer Agents Med Chem, vol. 12(9), pp. 1143-1155, Nov. 2012, doi:10.2174/187152012803529709
  6. A. Correia, D. Silva, A. Correia, M. Vilanova, F. Gärtner and N. Vale, “Study of New Therapeutic Strategies to Combat Breast Cancer Using Drug Combinations,” Biomolecules, vol. 8(4), Dec. 2018, Art no.175, doi:10.3390/biom8040175
  7. F.R. Li, F.X. Yu, S.T. Yao, Y.H. Si, W. Zhang and L.L. Gao, “Hyperin extracted from Manchurian Rhododendron leaf induces apoptosis in human endometrial cancer cells through a mitochondrial pathway,” Asian Pac J Cancer Prev, vol. 13(8), pp.3653-3656, Aug. 2012, doi:10.7314/apjcp.2012.13.8.3653
  8. Kirtonia, K. Gala, S.G. Fernandes, G. Pandya, A.K. Pandey, G. Sethi, E. Khattar and M. Garg, “Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics,” Sem Cancer Biol, vol. 68, pp. 258-278, Jan. 2021, doi:10.1016/j.semcancer.2020.04.006
  9. Verbaanderd, L. Meheus, I. Huys and P. Pantziarka, “Repurposing drugs in oncology: next steps,” Trends Cancer, vol. 3(8), pp. 543-54